Ecd conjugated anti cd45ra clone 2h4

The following antibodies were used: APC-H7-conjugated anti-CD3 (clone SK7), PB or FITC or PE-CF594-conjugated anti-CD4, PerCP-Cy5.5-conjugated anti-CD8 (clone SK1), (clone RPA-T4), (2G8), PE-conjugated anti-CCR6 (11A9), PE-Cy7-conjugated anti-CCR4 (1G1), V450-conjugated anti-HLA-DR (clone G46-6), PE-Cy7-conjugated anti-CD25 (clone M-A251), PeCy5-conjugated anti-CXCR4 (12G5), AlexaFluor700-conjugated anti-CCR5 (HEK/1/85a), PB or PeCy7 conjugated anti-PD-1 (EH12.1), anti-CCR7 (2H4), AlexaFluor700-conjugated anti-CD27 (M-T271), PE-conjugated anti-Ki67 (B56) purified coating anti-CD3 (clone UCHT1) and anti-CD28 (clone CD28.2) mAbs were purchased from BD (Becton Dickinson, San Diego CA, USA). PB-conjugated anti-CXCR3 (1C6) and PE or APC or PerCP-eFluor710-conjugated anti-CXCR5 mAbs were all purchased from Biolegend (Switzerland). ECD-conjugated anti-CD45RA (clone 2H4) was purchased from Beckman Coulter (Brea CA, USA) and anti-SAMHD1 (611-625) was purchased from Thermo Scientific (Switzerland).

The following antibodies were used: allophycocyanin (APC)-H7-conjugated anti-CD3 (clone SK7; BD), Pacific Blue (PB)-conjugated anti-CD19 (clone HIB19; BioLegend), PB-conjugated CD8 (clone RPA-T8; BD) fluorescein isothiocyanate (FITC)-conjugated anti-CXCR5 (clone RF8B2; BD), phycoerythrin (PE)-Cy7-conjugated anti-PD-1 (clone EH12.1; BD), Alexa 700 anti-CD4 (clone RPA-T4; BioLegend), APC-conjugated anti-CD32 (FUN-2; BioLegend), and phycoerythrin-Texas Red (ECD)-conjugated anti-CD45RA (clone 2H4; Beckman Coulter). An Aqua Live/Dead stain kit was used to determine the viability of cells. Cells were acquired on an LSRII flow cytometer using FACSDiva software (BD) and analyzed using FlowJo 9.7 (TreeStar Inc.) or sorted using FACSAria (BD). The CD32 antibody used in the present study is the same one used in the study by Descours et al., and this antibody does not discriminate between CD32a and CD32b. We used a fluorescence minus one (FMO) control to gate on CD32⁺ cells.